Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis Bioresearch, Syngene Partner on Cell Line Development

NEW YORK (GenomeWeb News) – Cellectis bioresearch and Indian contract research organization Syngene International said today they will co-develop novel genetically customized cell lines.

The collaboration between the two companies will leverage Paris-based Cellectis bioresearch's genome customization technology and Syngene's biology platform and capabilities to develop recombinant and knock-out cell lines for oncology and ADME-Tox-based drug discovery research.

Financial and other terms of the deal were not disclosed.

"This new partnership with Syngene International will enable us to mobilize each organizations' expertise and know-how and create synergies that will deliver hundreds of engineered cell lines for drug discovery and functional genomics," Cellectis bioresearch CEO Marc Le Bozec, said in a statement.

Cellectis bioresearch is a subsidiary of Cellectis.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.